HDAC9 and glioblastoma: Various HDAC inhibitors such as vorinostat (suberoylanilide hydroxamic acid, SAHA) and valproic acid are currently being tested in clinical trials on GBM (Chinnaiyan et al., 2012; Friday et al., 2012; Galanis et al., 2009; Moroni et al., 2013).